Alice Barber Lecture 2016 - 18th August
Fidgety Phil and head in the air Johnny: What is ADHD and why is it still so controversial
Presentor: Professor David Coghill (Financial Markets Foundation Chair of Developmental Mental Health
Departments of Paediatrics and Psychiatry, University of Melbourne
Professor of Child and Adolescent Psychiatry, Royal Children’s Hospital Melbourne)
Abstract: Attention deficit hyperactivity disorder has been recognised as an important cause of impairment for children and young people for many years for adults yet it remains very controversial within the public domain. Much of this controversy stems from the use of stimulant medications like methylphenidate (Ritalin) and dexamfetamine.
In this lecture I will explore the evidence that supports the validity of ADHD as a concept and disorder and look at the course of ADHD and its impact functioning across the lifespan. I will also discuss the current evidence that helps us understand some of the causes of ADHD and in particular the concept of heterogeneity that suggests that ADHD is in fact the common outcome of several causal different pathways.
I will finish by looking at the current evidence as it relates to the treatment of ADHD both with medication and non-medication treatments and make some practical suggestions about the way forward.
Date: Thursday 18th August, 5:00 - 6:00 PM
Venue: Ian Potter Auditorium, Kenneth Myer Building, Melbourne Brain Centre, 30 Royal Parade, Parkville
Registration: free event
About the presentor:
Professor Coghill took up post as the Financial Markets foundation Chair of Developmental Health at the University of Melbourne in February 2016. Prior to this he was professor of child and adolescent psychiatry at the University of Dundee in Scotland.
He has a particular interest in ADHD, disruptive behaviours and psychopharmacology. His work has focused on developing a better understanding of the pathophysiology of AD/HD, conduct disorder and depression using a range of approaches including neuropsychopharmacology, neuroimaging and genetics, patient reported outcomes and quality of life, pharmacogenomics, clinical trials, pharmacovigilance and pharmacoepidemiology.
David has always maintained a strong clinical presence and is particularly interested in translating clinical guidelines into clinical pathways that facilitate the rapid transfer of research evidence into routine clinical practice. He is the senior author of the Oxford Specialist Handbook on Child and Adolescent Psychiatry and recently completed his term as an editor of the Journal of Child Psychology and Psychiatry.